Orchard Therapeutics, a UK-based gene therapy spinout of University College London, closed a $150m oversubscribed series C round featuring medical marketing group Medison and healthcare management services provider Sphera Global Health Care on Monday.
The round was led by Deerfield Management. Medison participated through its strategic investment vehicle, Medison Ventures.
Temasek, the Singaporean state-owned investment firm, also participated, as did RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors, Cormorant Asset Management, ArrowMark Partners, Driehaus Capital Management, Ghost Tree Capital, Baillie…